AccuGenomics

AccuGenomics is a privately held diagnostics company that has developed a novel internal control technology, SNAQ-SEQ, designed to enhance the accuracy and reliability of next-generation sequencing (NGS) assays. By spiking synthetic DNA/RNA controls directly into each sample, the technology provides per-sample validation, enabling precise measurement of the limit of detection (LOD) and limit of blank (LOB) to reduce false calls. The company has commercialized its first product, Accukit™ Myeloid DNA, for actionable AML testing, and has expanded its platform to address ctDNA, CNVs, biocontaminants, and SARS-CoV-2 sequencing. A recent partnership with LGC Clinical Diagnostics underscores its transition to a commercial-stage entity with a focus on providing essential QC materials to the NGS market.

SNAQ-SEQ (Spike-in for NGS Assay Quality): A platform of synthetic DNA/RNA internal standards spiked directly into patient samples to measure technical and systemic errors, enabling per-sample determination of limit of detection (LOD) and limit of blank (LOB) for next-generation sequencing assays.

AccuGenomics competes in the NGS quality control market against large players like Agilent, Thermo Fisher Scientific, and Bio-Rad that offer external controls and reference materials. Its primary differentiation is the use of sample-spiked internal controls for per-sample error measurement, a niche not fully addressed by competitors who focus more on run-level QC and standardized reference samples.